For Immediate Release

DIMERIX PRESENTS AT ASX CEO CONNECT

MELBOURNE, Australia, 15 April 2025: Dimerix Limited (ASX: DXB), a biopharmaceutical company with a Phase 3 clinical asset in kidney disease, is pleased to advise that the Company will be presenting at ASX CEO Connect on Tuesday 15th April 2025.

Participants can register at the following link: https://event.asx.com.au/ceoconnectapril2025

The presentation is attached to this announcement.

For further information, please visit our website at www.dimerix.com or contact:

Dr Nina Webster
Dimerix Limited
Chief Executive Officer & Managing Director
Tel: +61 1300 813 321
E: investor@dimerix.com

Rudi Michelson
Monsoon Communications
Tel: +61 3 9620 3333
Mob: +61 (0)411 402 737
E: rudim@monsoon.com.au

Follow us on **LinkedIn** and **Twitter**

Authorised for lodgement by the Board of the Company

—END—

About Dimerix
Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company working to improve the lives of patients with inflammatory diseases, including kidney diseases. Dimerix is currently focussed on developing its proprietary Phase 3 product candidate DMX-200 (QYTOVRA® in some territories), for Focal Segmental Glomerulosclerosis (FSGS) kidney disease, and is also developing DMX-700 for respiratory disease. DMX-200 and DMX-700 were both identified using Dimerix' proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities.

About DMX 200
DMX 200 is the adjunct therapy of a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker - the standard of care treatment for hypertension and kidney disease. DMX 200 is protected by granted patents in various territories until 2032, with patent applications submitted globally that may extend patent protection to 2042, in addition to any exclusivity period that may apply in key territories. In 2020, Dimerix completed two Phase 2 studies: one in FSGS and one in diabetic kidney disease, following a successful Phase 2a trial in patients with a range of chronic kidney diseases in 2017. No significant adverse safety events were reported in any trial, and all studies resulted in encouraging data that could provide meaningful clinical outcomes for patients with kidney disease.

About FSGS

FSGS is a rare disease that attacks the kidney's filtering units, where blood is cleaned (called the 'glomeruli'), causing irreversible scarring. This leads to permanent kidney damage and eventual end-stage failure of the organ, requiring dialysis or transplantation. For those diagnosed with FSGS the prognosis is not good. The average time from a diagnosis of FSGS to the onset of complete kidney failure is only five years and it affects both adults and children as young as two years old.[1] For those who are fortunate enough to receive a kidney transplant, approximately 60% will get re-occurring FSGS in the transplanted kidney.[2] At this time, there are no drugs specifically approved for FSGS anywhere in the world, so the treatment options and prognosis are limited.

FSGS is a billion-dollar plus market: the number of people with FSGS in the US alone is just over 80,000,[1] and worldwide about 220,000.[3] The illness has a global compound annual growth rate of 8%, with over 5,400 new cases diagnosed in the US alone each year.[4] Because there is no effective treatment, Dimerix has received Orphan Drug Designation for DMX 200 in both the US and Europe for FSGS. Orphan Drug Designation is granted to support the development of products for rare diseases and qualifies Dimerix for various development incentives including: seven years (FDA) and ten years (EMA) of market exclusivity if regulatory approval is received, exemption from certain application fees, and a fast-tracked regulatory pathway to approval. Dimerix reported positive Phase 2a data in FSGS patients in July 2020.

References

1 *Guruswamy Sangameswaran KD, Baradhi KM. (2021) Focal Segmental Glomerulosclerosis), online: https://www.ncbi.nlm.nih.gov/books/NBK532272/*

2 *Front. Immunol., (July 2019) | https://doi.org/10.3389/fimmu.2019.01669*

3 *Delve Insight Market Research Report (2022): Focal segmental glomerulosclerosis (FSGS) – Market Insight, Epidemiology and market forecast – 2032; https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-market;*

4 *Nephcure Kidney International (2020); Focal Segmental Glomerulosclerosis, online https://nephcure.org/livingwithkidneydisease/understanding-glomerular-disease/understanding-fsgs/*





Dimerix

(ASX:DXB)

Developing new therapies to treat inflammatory causes of kidney disease with unmet clinical needs

ASX CEO Connect

15 April 2025

Authorised for lodgement by the Board of the Company

Forward looking statements

This presentation includes forward-looking statements that are subject to risks and uncertainties. Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, Dimerix can give no assurance that these expectations will prove to be correct.

Actual results could differ materially from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, results of clinical trials, risks associated with patent protection, future capital needs or other general risks or factors, along with those factors outlined in the most recent Dimerix Limited Annual Report.

Overview | Phase 3 Global Opportunity



Lead Drug Candidate

- DMX-200 is currently in a **Phase 3 clinical trial** for focal segmental glomerulosclerosis (FSGS)
- DMX-200 has **orphan drug designation** in key territories

FSGS Indication

- FSGS is a **rare disease** that causes scar tissue of kidneys, which leads to irreversible kidney damage[1]
- FSGS kidney damage can lead to dialysis, kidney transplants or death[1]
- There are currently **no approved treatments** available to treat FSGS

Commercial and Technical Validation

- **Three commercial licensing deals** achieved**:**
  - ~$458m in total upfront & potential milestone payments + royalties[2]
- **Successful Phase 3 interim analysis**: Analysis showed DMX-200 had performed better than placebo in reducing proteinuria[3]

Dimerix

1. Guruswamy Sangameswaran KD, Baradhi KM. Focal Segmental Glomerulosclerosis (July 2021), online: https://www.ncbi.nlm.nih.gov/books/NBK532272/; 2. ASX release 05 October 2023, 27 May 2024 and 07 January 2025; 3. Predictive Power statistical model, using industry standard as set by the independent renal biostatistician consultant for Dimerix, ASX release 11 March 2024

Focal Segmental Glomerulosclerosis (FSGS)

What is FSGS?

Focal	**= some**
Segmental	**= sections**
Glomerulo	**= of the kidney filtering units**
Sclerosis	**= are scarred**

How do you measure kidney function?

- Historically, measured using “hard” endpoints for kidney disease (kidney failure) -which may not be reached for decades[1]
- Regulatory agencies and national bodies now consider estimated glomerular filtration rate (eGFR) and proteinuria decline as surrogate end points for kidney failure in certain conditions[2]

FSGS Kidney Damage[3]



Dimerix

1. Hartung E, (2015), Pediatric Nephrology volume 31, pages381–391 DOI: 10.1007/s00467-015-3104-8; 2. Thompson A et al, (2019) Am J Kidney Dis.; 75(1):4-5: doi.org/10.1053/j.ajkd.2019.08.007; 3. Nephcure FSGS living with the disease (2024) at https://nephcure.org/livingwithkidneydisease/ns-and-other-glomerular-diseases/understanding-fsgs/ ; 4. Lewis, E. J. et al. (2001), New Engl J Medicine 345, 851–860; 5. Rare Disease Information Center: Number of recipients of special medical expenses (designated intractable disease) certificates: https://www.nanbyou.or.jp/entry/5354

Significance of stabilising eGFR curve: primary endpoint



- Kidney function can be measured using estimated glomerular filtration rate (eGFR):
  - how many millilitres of blood is filtered by the kidney per minute
- eGFR slope naturally declines as we age[1]
- In FSGS patients, it is crashing

Treatments, such as DMX-200, aim to bring the FSGS slope back up towards that which occurs with natural aging:

- This can add years to the life of the kidney
- Potential to delay dialysis and/or kidney transplant

Dimerix

1. National Kidney Foundation: Estimated Glomerular Filtration Rate (eGFR): https://www.kidney.org/atoz/content/gfr

Significance of decreasing proteinuria: primary endpoint

Why are kidneys important?

- A healthy kidney is a good filter and allows little to no protein in the urine[1]



- When kidneys are damaged, protein can leak into the urine causing proteinuria
- Proteinuria represents an important early marker of kidney function[2]

Symptoms of proteinuria[1]

	More frequent urination		Shortness of breath
	Nausea and vomiting		Tiredness
	Swelling in the face, stomach, feet and/or ankles		Lack of appetite
	Muscle cramping at night		Foamy or bubbly urine
	Puffiness around the eyes, especially in the morning		

DMX-200 aims to reduce the inflammation of the kidneys:

- ➢ if DMX-200 reduces inflammation, the amount of proteinuria should decrease

Dimerix

1. Nephcure FSGS living with the disease (2024) at https://nephcure.org/livingwithkidneydisease/ns-and-other-glomerular-diseases/understanding-fsgs/ 2. Guruswamy Sangameswaran KD, Baradhi KM. Focal Segmental Glomerulosclerosis (July 2021), online: https://www.ncbi.nlm.nih.gov/books/NBK532272/;

ACTION3 phase 3 clinical trial – next steps

FSGS CLINICAL STUDY

A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB

Background

- Patients recruited, then screened and stabilised on background medications
- Patients randomised to receive drug or placebo
- DXB remains blinded at all times during study

Phase 3 Trial Timeline



★ *Potential to submit for conditional marketing approval [3]*

Dimerix

1. Interim Phase 3 analysis data does not guarantee a statistically significant outcome at the end of the trial, ASX release 11 March 2024; 2. ASX release 30 December 2024 and subject to FDA feedback; 3. The potential for accelerated (or conditional) approval submissions, following the second interim analysis and any required unblinding, will be assessed based on recommendations of the IDMC and discussions with the appropriate regulatory authorities such as the FDA in the US; 4. Regardless of any accelerated (conditional) approval potential, ACTION3 study will complete full 2 year analysis and regulatory submission for potential traditional (full) approval; uPCR = urinary proteinuria; eGFR = estimated glomerular filtration rate (kidney function);

ACTION3 current status

FSGS CLINICAL STUDY

286

Total number of patients to be recruited, randomised and dosed - anticipated in Q3 2025[1]

176

Patients recruited, randomised and dosed[2]

40

Patients completed full 2 year ACTION3 study treatment[2]

39

Patients enrolled over into Open Label Extension Study[2]

Confirmed:

- Positive Type C meeting held in March 2025 with US Food & Drug Administration (FDA) on proteinuria trial endpoints, and potential for accelerated approval for DMX-200
- Dimerix intends to update the market on meeting outcomes upon the receipt of the formal FDA meeting minutes - anticipated within 30 days of the meeting (i.e. April 2025)

1. ASX release 30 Dec 2024; 2. as at 11 Apr 2025

Summary of licensing deals

Licensing deals collectively valued up to
AU$458 million in total upfront and potential milestone fees + royalties[1]

Advanz[2]	Taiba[3]	Fuso[4]	Other licensing deals
EU, CA, AU, NZ	GCC, Iraq	Japan	
AU$10.8m[2]	AU$0.5 million[3]	AU$7.2 million[4]	?
Upfront	Upfront	Upfront + 1st milestone	
Up to AU$219 million[2]	Up to AU$120 million[3]	Up to AU$100 million[4]	?
Milestones	Milestones	Milestones	
Escalating mid-teen-20%	Starting at 30%	Between 15-20%	?
Royalties	Royalties	Royalties	



Significant potential additional global value remains, as Dimerix pursues and progresses licensing opportunities with potential partners outside the licensed territories, including in US and Mainland China

1. ASX release 7 January 2025; 2. Based on Euro conversions & further terms outlined in ASX Announcement on 5 October 2023; 3. Based on US dollar conversions & further terms outlined in ASX Announcement on 27 May 2024; 4. Based on Japanese ¥ Yen conversions & further terms outlined in ASX Announcement on 7 January 2025

Corporate overview

Ticker Symbol	ASX: DXB
Cash Balance (Dec24)*	$21.11 million
Market Capitalisation[1]	~A$218 million
Share price[1]	~A$0.39
Total ordinary shares on issue[1]	559,274,262
Average Daily Liquidity by value for past 30 trading days[2]	~A$0.87 million

SHARE PRICE

SUBSTANTIAL SHAREHOLDERS[3]

Position	Holder Name	Holding	% IC
1	Mr P Meurs	75,679,506	13.5%
TOTAL (TOP 5) Shareholders		**130,906,002**	**23.4%**

*Cash balance does not include:

- *~$3.1 million - upfront fee received from Fuso development & licensing agreement (ASX release 4 March 2025)*
- *~$4.1 million - payment anticipated on 1st clinical site opening in Japan from Fuso licensing agreement Q2 2025*
- *Up to $6.5 million - potential conversion of 41,920,587 DXB options (as at 31 December 2024) exercisable at 15.4c per share (expire 30June2025)*

Dimerix

1. As at 10 April 2025; 2. Past 30 trading days liquidity as at 1 April 2025; 3. Shareholder register as at 1 April 2025

Potential catalysts



2025

Q1/Q2 2025

- **Complete: FDA meeting** held – formal minutes anticipated April 2025[1]
- ~AU$4.1 million[2] **development milestone** anticipated from FUSO[1]

Q3/Q4 2025

- Planned blinded **interim data collection** anticipated in August 2025, subject to FDA feedback[3]
- Potential for **accelerated (or conditional) approval** submission, subject to FDA feedback[1,3]
- **Full study recruitment** of 286 adult patients anticipated in CYQ3 2025[3]

Potential upside – at any time

- Additional **licensing partners** for DMX-200: Dimerix continues to pursue potential licensing opportunities in un-licensed territories, including US & China

Dimerix

1. ASX Investor Presentation 26 Feb 2025; 2. Based on XE exchange rates & further terms outlined in ASX Announcement on 07 Jan 2025; 3. ASX release 30 Dec 2024

Dimerix

(ASX:DXB)



A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on inflammatory disease treatments such as kidney and respiratory diseases.

SCAN ME

WELL POSITIONED **TO DELIVER** AGAINST STRATEGIC PLAN

ESG Statement

Dimerix is committed to integrating Environmental, Social and Governance (ESG) considerations across the development cycle of its programs, processes and decision making. The Dimerix commitment to improve its ESG performance demonstrate a strong, well-informed management attitude and a values led culture that is both alert and responsive to the challenges and opportunities of doing business responsibly and sustainably.

Dimerix HQ
425 Smith St, Fitzroy 3065
Victoria, Australia
T. 1300 813 321
E. investor@dimerix.com